Evidence map›Paper›PMID 35530043›Full record

ArticleFrontiers in medicine2022

Early COPD Risk Decision for Adults Aged From 40 to 79 Years Based on Lung Radiomics Features.

Yingjian Yang, Wei Li, Yingwei Guo, Yang Liu, Qiang Li, Kai Yang, Shicong Wang, Nanrong Zeng, Wenxin Duan, Ziran Chen and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. High prevalence of respiratory diseases: a population-based ecological study, Sertão do Araripe, 2008-2019.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Yingjian YangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Wei LiMedical Device Innovation Center, Shenzhen Technology University, Shenzhen, China.
Yingwei GuoCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Yang LiuMedical Device Innovation Center, Shenzhen Technology University, Shenzhen, China.
Qiang LiCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Kai YangShenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital, Shenzhen, China.
Shicong WangMedical Device Innovation Center, Shenzhen Technology University, Shenzhen, China.
Nanrong ZengMedical Device Innovation Center, Shenzhen Technology University, Shenzhen, China.
Wenxin DuanMedical Device Innovation Center, Shenzhen Technology University, Shenzhen, China.
Ziran ChenMedical Device Innovation Center, Shenzhen Technology University, Shenzhen, China.
Huai ChenDepartment of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xian LiDepartment of Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wei ZhaoMedical Engineering, Liaoning Provincial Crops Hospital of Chinese People's Armed Police Forces, Shenyang, China.
Rongchang ChenShenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital, Shenzhen, China.
Yan KangCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Shenzhen Technology University · CNGuangzhou Medical University · CNChinese People's Armed Police ForceJinan University · CNNortheastern University · CNShenZhen People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic obstructive pulmonary disease (COPD), a preventable lung disease, has the highest prevalence in the elderly and deserves special consideration regarding earlier warnings in this fragile population. The impact of age on COPD is well known, but the COPD risk of the aging process in the lungs remains unclear. Therefore, it is necessary to understand the COPD risk of the aging process in the lungs, providing an early COPD risk decision for adults. Methods: COPD risk is evaluated for adults to make an early COPD risk decision from the perspective of lung radiomics features. First, the subjects are divided into four groups according to the COPD stages. Their ages are divided into eight equal age intervals in each group. Second, four survival Cox models are established based on the lung radiomics features to evaluate the risk probability from COPD stage 0 to suffering COPD and COPD stages. Finally, four risk ranks are defined by equally dividing the COPD risk probability from 0 to 1. Subsequently, the COPD risk at different stages is evaluated with varying age intervals to provide an early COPD risk decision. Results: The evaluation metrics area under the curve (AUC)/C index of four survival Cox models are 0.87/0.94, 0.84/0.83, 0.94/0.89, and 0.97/0.86, respectively, showing the effectiveness of the models. The risk rank levels up every 5 years for the subjects who had suffered COPD after 60. For the subjects with COPD stage 0, the risk rank of suffering COPD stage I levels up every 5 years after the age of 65 years, and the risk rank of suffering COPD stages II and III & IV levels up every 5 years after the age of 70 years. Conclusion: Once the age is above 60 years, the patients with COPD need to take action to prevent the progress and deterioration of COPD. Once the age is above 65 years, the patients with COPD stage 0 need to take precautions against COPD.

Indexed as

agingCOPD riskCOPD stage (GOLD)early decisionLassoradiomicssurvival Cox model

Identifiers

PMID35530043
PMCPMC9069013
OpenAlexW4224231953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.